根据名称进行药物检索

Nifedical XL与高血压

Nifedical XL与高血压安全配伍检测的结果。

检测结果:

Nifedical XL <> 高血压

现实性: 03.07.2019 评论家: 医学副博士Shkutko P.M., in

通过权威的信息来源 Drugs.com、Rxlist.com、Webmd.com、Medscape.com，在进行所选药物与这种食物或生活方式互相作用检测时，发现一些会产生负面影响或对身体危害的禁忌症及副作用。

用户:

长期治疗高血压，只能的缓释制剂的硝苯地平应用。美国国家心脏、肺和血液研究所和美國食品藥品管理局心血管和肾脏毒品咨询委员会已发出警告，反对使用立即释硝苯地平为此目的基础上审查的三个流行病学研究的患者患有高血压和心绞痛不稳定谁是处理与钙通道阻滞剂(建行)和至少两个荟萃分析的随机对照试验，包括接收患者建行. 两个案例控制研究中发现风险增加的心肌梗死(MI)患者采取立即释硝苯地平，虽然第三没有。使用的即时释放硝苯地平(经口头或舌下)也是禁忌急性降低血压。深刻的低血压、急性心肌梗死，死亡人数已报告在硝苯地平是使用这种方式。

医界专家:

来源

Grossman E, Messerli FH, Grodzicki T, Kowey P "Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?" JAMA 276 (1996): 1328-31
Schwartz M, Naschitz JE, Yeshurun D, et al "Oral nifedipine in the treatment of hypertensive urgency: cerebrovascular accident following a single dose." Arch Intern Med 150 (1990): 686-7
American Health Consultants "Do calcium-channel blockers increase the risk of myocardial infarctions?" Internal Medicine Alert 17 (1995): 49-50
Zangerle KF, Wolford R "Syncope and conduction disturbances following sublingual nifedipine for hypertension." Ann Emerg Med 14 (1985): 1005-6
Miller JL "FDA committee recommends stronger warning against inappropriate use of immediate-release nifedipine: no changes for other calcium-channel blockers." Am J Health Syst Pharm 53 (1996): 599-600
Carpi J "Calcium channel blocker debate refuses to die." Internal Medicine News June 15 (1995): 1(col4),2(col3)
Bloomfield RL, Carter J "Hypertensive urgencies: how to give a low dose of short-acting nifedipine." Geriatrics 51 (1996): 10
Jick H, Derby LE, Gurewich V, Vasilakis C "The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension." Pharmacotherapy 16 (1996): 321-6
Wachter RM "Symptomatic hypotension induced by nifedipine in the acute treatment of severe hypertension." Arch Intern Med 147 (1987): 556-8
Aromatorio GJ, Uretsky BF, Reddy PS "Hypotension and sinus arrest with nifedipine in pulmonary hypertension." Chest 87 (1985): 265-7
Peters FP, de Zwaan C, Kho L "Prolonged QT interval and ventricular fibrillation after treatment with sublingual nifedipine for malignant hypertension" Arch Intern Med 157 (1997): 2665-6
Marwick C "FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards." JAMA 275 (1996): 423-4
Bradbury J "Sublingual short-acting nifedipine causes serious side-effects." Lancet 348 (1996): 1159
Buring JE, Glynn RJ, Hennekens CH "Calcium channel blockers and myocardial infarction: a hypothesis formulated but not yet tested." JAMA 274 (1995): 654-5
"Product Information. Adalat (nifedipine)." Bayer, West Haven, CT.
Kloner RA "The issue of the cardiovascular safety of dihydropyridines." Am J Hypertens 9 (1996): s182-6
"Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.
Woodmansey P, Channer KS "Nifedipine and hypotension." Lancet 338 (1991): 763-4
Miller JL "FDA committee recommends stronger warnings against inappropriate use of immediate-release nifedipine." Am J Health Syst Pharm 53 (1996): 599-600
Psaty BM, Heckbert SR, Koepsell TD, et al. "The risk of myocardial infarction associated with antihypertensive drug therapies." JAMA 274 (1995): 620-5